Literature DB >> 7518457

Identification of a novel type of alternative splicing of a tyrosine kinase receptor. Juxtamembrane deletion of the c-met protein kinase C serine phosphorylation regulatory site.

C C Lee1, K M Yamada.   

Abstract

We have detected a novel type of structural variant of the tyrosine kinase receptor for c-met, also known as the hepatocyte growth factor receptor, in mouse tissues. The cDNA of the variant transcript of c-met lacks 141 base pairs, which predicts an in-frame deletion of 47 amino acids in the juxtamembrane region of the cytoplasmic domain. Sequence analysis of genomic DNA containing the c-met locus revealed that the absence of a discrete exon is responsible for this 141-base pair deletion and that alternative splicing leads to production of two forms of transcript. These two forms of transcript are designated as c-metsm (for small) and c-metlg (for large) to distinguish the absence or presence of the 141-base pair segment, respectively. The c-metsm variant is present in adult mouse tissues including kidney, liver, and brain as well as in 9-10-day-old embryos. In all cases, expression of c-metsm was lower than that of the normal transcript, c-metlg. An antiserum against mouse c-Met protein immunoprecipitated corresponding protein forms of approximately 152 and approximately 145 kDa from whole kidney lysate under reducing conditions. The size difference of approximately 7 kDa between these isoforms corresponds to the predicted difference of 47 amino acids. The presence of this shorter variant transcript and its corresponding protein isoform in a variety of normal tissues suggests a physiological role. The deleted region in the cytoplasmic domain of c-metsm contains a sequence motif (S985ARS) for protein kinase C phosphorylation that has recently been shown to play a key role in the down-regulation of hepatocyte growth factor receptor kinase activity. The identification of this novel isoform, c-metsm, demonstrates that a tyrosine kinase receptor can achieve additional diversity by alternative splicing at a key regulatory site in its cytoplasmic domain.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7518457

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors.

Authors:  V Wallenius; M Hisaoka; K Helou; G Levan; N Mandahl; J M Meis-Kindblom; L G Kindblom; J O Jansson
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

Review 2.  MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy.

Authors:  Sara Pilotto; Anastasios Gkountakos; Luisa Carbognin; Aldo Scarpa; Giampaolo Tortora; Emilio Bria
Journal:  Ann Transl Med       Date:  2017-01

Review 3.  Biology of MET: a double life between normal tissue repair and tumor progression.

Authors:  Iacopo Petrini
Journal:  Ann Transl Med       Date:  2015-04

Review 4.  Hepatocyte growth factor/scatter factor-induced intracellular signalling.

Authors:  K A Stuart; S M Riordan; S Lidder; L Crostella; R Williams; G G Skouteris
Journal:  Int J Exp Pathol       Date:  2000-02       Impact factor: 1.925

5.  A novel isoform of met receptor tyrosine kinase blocks hepatocyte growth factor/Met signaling and stimulates skeletal muscle cell differentiation.

Authors:  Minseon Park; Bok-Soon Lee; Soung-Hoo Jeon; Hyun-Ja Nam; Gwang Lee; Chul-Ho Kim; Hyeseong Cho; Jae-Ho Lee
Journal:  J Biol Chem       Date:  2014-12-03       Impact factor: 5.157

6.  Mutations Preventing Regulated Exon Skipping in MET Cause Osteofibrous Dysplasia.

Authors:  Mary J Gray; Peter Kannu; Swarkar Sharma; Christine Neyt; Dongping Zhang; Nandina Paria; Philip B Daniel; Heather Whetstone; Hans-Georg Sprenger; Philipp Hammerschmidt; Angela Weng; Lucie Dupuis; Rebekah Jobling; Roberto Mendoza-Londono; Michael Dray; Peiqiang Su; Megan J Wilson; Raj P Kapur; Edward F McCarthy; Benjamin A Alman; Andrew Howard; Gino R Somers; Christian R Marshall; Simon Manners; Adrienne M Flanagan; Karl E Rathjen; Lori A Karol; Haemish Crawford; David M Markie; Jonathan J Rios; Carol A Wise; Stephen P Robertson
Journal:  Am J Hum Genet       Date:  2015-12-03       Impact factor: 11.025

Review 7.  MET meet adaptors: functional and structural implications in downstream signalling mediated by the Met receptor.

Authors:  Victor Martin Bolanos-Garcia
Journal:  Mol Cell Biochem       Date:  2005-08       Impact factor: 3.842

8.  Alternative splicing in oncogenic kinases: from physiological functions to cancer.

Authors:  Sabine Druillennec; Coralie Dorard; Alain Eychène
Journal:  J Nucleic Acids       Date:  2011-10-05

9.  Exploratory analysis of introducing next-generation sequencing-based method to treatment-naive lung cancer patients.

Authors:  Yufang Feng; Gaohua Feng; Xiaoling Lu; Wenxia Qian; Junyi Ye; Carmen Areses Manrique; Chunping Ma; Yadong Lu
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

Review 10.  Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges.

Authors:  Toshio Fujino; Kenichi Suda; Tetsuya Mitsudomi
Journal:  Lung Cancer (Auckl)       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.